induced models for psoriasis in mice. 14, [16] [17] [18] IL-17A was formerly thought to be only generated by a subset of CD4 + T cells (Th17), but by now we know that also dendritic cells, natural killer cells, macrophages, and γδ-T cells are able to generate IL-17A. 19 Members of the IL-17 family were described to be produced also by keratinocytes, endothelial cells, and neurons. 9 The efficacy of IL-17A neutralization and anti-IL17-receptor antibody therapy in human psoriasis 2, 20 and the finding that mice lacking the IL-17 receptor alpha develop blunted imiquimod-induced psoriasis-like skin disease as compared with control mice 21 suggest that IL-17A is an important proinflammatory cytokine in the pathogenesis of psoriasis. To further investigate these mechanisms, we generated a mouse strain conditionally overexpressing IL-17A in keratinocytes (K14-IL-17A ind/+ mice). 22 In a conditional knock-in approach, we introduced the targeting construct (IL-17A cDNA) into the endogenous gt(ROSA)26Sor locus. 23 On Cre-mediated recombination (in our case here, by the K14 Cre-recombinase), a lox-P-flanked transcriptional STOP cassette is excised 5′ of the IL-17A cDNA insert and an IRES-enhanced green fluorescent protein element, leading to a dual expression of IL-17A and enhanced green fluorescent protein under the control of the chicken β-actin promoter. 23 The resulting K14-IL-17A ind/+ mouse strain, which thus overexpresses IL-17A in keratinocytes, has a skin phenotype mimicking many hallmark features of severe human psoriasis ( Figure ID in the online-only Data Supplement). There is growing evidence that inflammation in the skin may also affect the vasculature 24 and that IL-17A could be of importance in linking skin disease to vascular disease/inflammation. 8 As severe psoriasis (but not mild psoriasis) is considered to be an independent risk factor for cardiovascular mortality, 6 the K14-IL-17A ind/+ mice which develop a severe form of psoriasis-like skin disease seemed to be an ideal model to study the correlation between psoriasis and vascular disease in the mouse model. We therefore sought to determine whether IL-17A drives vascular inflammation and dysfunction in severe psoriasis-like skin inflammation using the K14-IL-17A ind/+ mice.
We here show that overexpression of IL-17A in keratinocytes induces systemic vascular inflammation, endothelial dysfunction, and arterial hypertension driven by MPO + cells, leading to increased mortality. We also confirmed in a cohort of patients with severe psoriasis an independent correlation of psoriasis with arterial hypertension. Short-time depletion of neutrophil granulocytes by anti-GR-1 antibody injection and long-term pharmacological antagonization of tumor necrosis factor-α (TNF-α) and IL-6 attentuated oxidative stress and partially vascular disease in K14-IL-17A ind/+ mice. The sequence of events downstream of IL-17A could be mechanistic players to target cardiovascular sequelae of psoriasis.
Material and Methods
A description of the material and methods is provided in the onlineonly Data Supplement.
Results

Impaired Vascular Function and Increased Reactive Oxygen Species Formation in Mice With Psoriasis-Like Phenotype
In mice, Cre-mediated IL-17A overexpression in keratinocytes results in skin inflammation 22 ( Figure IA in the online-only Data Supplement) comparable to severe human psoriasis displaying hallmark features of the disease like an acanthotically thickened epidermis, hyper-and parakeratosis, multiple (epi)dermal neutrophilic abscesses, increased vessel formation in the skin, and an accumulation of CD11b + , F4/80 + , and GR1 + inflammatory myeloid cells in the inflamed skin ( Figure IB , IC, and ID in the online-only Data Supplement). K14IL-17A ind/+ mice also present with typical comorbidities of psoriasis-like conjunctivitis and arthritis ( Figure ID in the online-only Data Supplement) stressing the realistic patho-physiological relevance of this mouse model. Any important ectopic expression of IL-17A (other than keratinocyte-derived) was ruled out using in vivo imaging technology with reporter-Cre strains (see Figure II in the online-only Data Supplement). Thus, the K14IL-17A ind/+ mice represent a useful instrument for the experimental analysis of psoriasis-like skin disease and its sequela.
Vascular relaxation studies of the aortas revealed severe endothelial dysfunction as demonstrated by the decreased responsiveness to the endothelium-dependent vasodilator acetylcholine in K14IL-17A ind/+ mice ( Figure 1A ). Compared with controls, reactive oxygen species (ROS) levels were higher in the blood of K14IL-17A ind/+ mice at basal level and on stimulation with the phorbolester phorbol 12,13-dibutyrate, a protein kinase C-dependent activator of the superoxide producingenzyme nicotinamide dinucleotide phosphate (NADPH) oxidase ( Figure 1B ). We also found increased NADPH oxidase activity in cardiac homogenates of the K14IL-17A ind/+ mice compared with control mice ( Figure 1C ). Elevated blood ROS levels were accompanied by increased number of circulating CD11b +mainly GR-1 + -myelomonocytic cells (Figure 2A and 2B) because of activation via their NADPH oxidase. 25 Systemically, the numbers of both Ly6G + CD11b + and Ly6C + CD11b + leukocytes were significantly increased ( Figure 2C and 2D).
In parallel, we established increased IL-17A levels in the serum of the K14IL-17A ind/+ mice ( Figure ID in the onlineonly Data Supplement). Also for humans, it has been reported that serum IL-17 is higher in psoriasis patients compared with healthy controls. 26 A positive correlation between the psoriasis area and severity index score and the serum IL-17 level in psoriasis vulgaris was described. 27 IL-6 serum levels were increased in the K14IL-17A ind/+ mice ( Figure ID in the online-only Data Supplement), and TNF-α was elevated by trend in the serum and in the skin ( Figure IIIA and IIIB in the online-only Data Supplement). These cytokines have been described to be elevated 
Increased Vascular Oxidative Stress and Reduced Vascular Nitric Oxide Bioavailability in K14IL-17A ind/+ Mice
Endothelial dysfunction in the setting of the psoriasis-like skin disease was accompanied by increased vascular superoxide (O 2 · − ) levels throughout the aorta ( Figure 3A ) and by higher levels of 3-nitrotyrosine in intima and the media ( Figure 3B ) compatible with increased formation of the nitric oxide (NO·)/O 2 · − reaction product peroxynitrite (ONOO − ). Inducible NO synthase (iNOS) was found to be upregulated in the outer part of the aortic vessel wall of K14IL-17A ind/+ mice compared with control mice ( Figure 3C ). We also found elevated levels of serum nitrite ( Figure IIIC in the online-only Data Supplement). Increased peroxynitrite formation causes, for example, tyrosine nitration of the prostacyclin synthase, uncoupling of the NO-synthase, and inhibition of the soluble guanylyl cyclase, contributing to vascular endothelial dysfunction. 29 Decreased vascular NO bioavailability leads to an inhibition of the NO/ cGMP/cGK-I signaling pathway as indicated by a reduced vasodilator-stimulated phosphoprotein phosphorylation in aortas from K14IL-17A ind/+ mice ( Figure 3D ). 30 Increased oxidative stress within the vasculature was accompanied by an increased expression of the oxidative stress response protein hemeoxygenase-1 in aortas ( Figure 3E ).
Infiltration of Neutrophils to the Skin Is Accompanied by Increased Levels of Neutrophil Granulocytes in the Aorta of K14IL-17A ind/+ Mice
Besides an upregulation of the catalytic subunit of the phagocytic NADPH-oxidase (gp91 phox ) in aortas of K14IL-17A ind/+ mice ( Figure 4A ), myeloperoxidase (MPO)-positive vesicles or cellular structures were increased in the adventitial layer neighboring the perivascular adipose tissue ( Figure 4B ).
CD11b + GR1 + F4/80 − cells-most likely representing neutrophil granulocytes-accumulated in the aortas of the K14IL-17A ind/+ mice ( Figure 4C ). These cells were also upregulated in the skin ( Figure IB in the online-only Data Supplement) reminiscent of the accumulation of neutrophil granulocytes seen in the skin lesions of psoriasis patients.
IL-17A-Driven Psoriasis-Like Disease Is Accompanied by Arterial Hypertension, Cardiomyocyte Hypertrophy, and Premature Death
Vascular dysfunction in the K14IL-17A ind/+ mice was accompanied by an increased systolic blood pressure compared with controls ( Figure 5A ). 31 Renal function was not altered ( Figure  IVA in the online-only Data Supplement). Most likely as a consequence of arterial hypertension, we detected a significant increase in the heart weight of the K14IL-17A ind/+ mice compared with controls, resulting in a significantly elevated heart-body ratio ( Figure 5B ). There was no evidence for myocarditis in K14IL-17A ind/+ mice compared with controls (upper panels); only perivascular inflammation was visible in K14IL-17A ind/+ mice (lower panel; Figure 5C ), as well as a significant cardiomyocyte hypertrophy ( Figure 5C and 5D) in K14IL-17A ind/+ mice. Compared with healthy littermate control animals, K14IL-17A ind/+ mice showed a reduced lifespan ( Figure 5E ). The mice seemed to die from sudden causes because death occurred without previous prefinal morbidity or decay of the mice. Neither histological analysis of the different organs of the K14IL-17A ind/+ mice nor the analysis of the clinical chemistry laboratory values of the blood of the K14IL-17A ind/+ mice delivered clear evidence for the cause of the earlier death ( Figure V in the online-only Data Supplement), making sudden cardiac death a possible reason for the increased mortality of K14IL-17A ind/+ mice.
Increased Cardiovascular Risk Profile in Psoriasis Patients
In a translational approach, we calculated the 10-year risk for development of CVD (as indexed by coronary heart disease, stroke, peripheral artery disease, or heart failure) by a score based on the Framingham Heart Study. 32 Retrospectively, we found an elevated risk for the hospitalized psoriatic patients of the Department of Dermatology, University Medical Center Mainz, compared with an age-and sex-matched populationbased sample without psoriasis from the Gutenberg Health A, Blood of K14-IL-17A ind/+ and control mice was analyzed for CD11b, F4/80, and GR1 via flow cytometric analysis, after outgating dead cells and pregating on the B220 − and CD3 − / CD90.2 − cells. One representative plot is shown per group. Percentage given in the plot itself is related to the pregate. (IL-17A ind/+ versus K14-IL-17A ind/+ : 65.4% ±6.6% versus 80.0%±4.9% CD11b + cells, 31.9%±4.4% versus 82.8%±1.0% GR-1 + of CD11b + , 22.1%±7% versus 5.3%±1.6% F40/80 + of CD11b + ; n=10 mice per group). B, Statistics for the individual populations are calculated as percentage of the living cells using the Student t test (IL-17A ind/+ versus K14-IL-17A ind/+ : 16.6%±1.4% versus 55%±3.4% CD11b + cells of all life cells in total blood, 4.8%±0.5 versus 45.7%±3.0% GR-1 + of all life cells in total blood, 3.6%±1.4% versus 3.1%±1.0% F4/80 + of all life cells in total blood; n=10 mice per group). C, Statistical analysis is given for the percentage of CD11b + Ly6G + Ly6C + and the Ly6C + Ly6G − cells in the blood of K14-IL-17A ind/+ and control mice analyzed by flow cytometry analysis (Student t test, n=4-5 mice per group). The representative plots are shown in Figure 6A . D, Splenocytes of K14-IL-17A ind/+ and control mice were analyzed for CD11b, Ly6G, and Ly6C. Dead cells were out-gated, and it was pregated on the B220 − and CD90.2 − cells. One representative plot is shown per group. Percentage given in the plot itself is related to the pregate. Statistical analysis below shows the total cell number of the CD11b + , Ly6G + , and Ly6C − cells per spleen (n=7 mice per group, Student t test). December 2014 psoriasis patients more often had other classical cardiovascular risk factors like smoking, diabetes mellitus, or obesity (all P<0.0001;. Figure for classical cardiovascular risk factors (P≤0.003; Figure  VIC in the online-only Data Supplement). The odds ratio for hypertension among psoriasis patients versus the nonpsoriatic sample was 1.6 (95% confidence interval, 1. 
Neutrophil Depletion Leads to a Reduction of Oxidative Stress Levels in the Blood
Systemic application of the antigranulocyte receptor-1 monoclonal antibody RB6-8C5 (anti-GR1) 34 over 24 hours lead to a systemic depletion of the Ly6G + CD11b + neutrophil granulocytes and partially also of the Ly6G − Ly6C + CD11b + cells in the blood ( Figure 6A ). ROS levels in the blood of the K14IL-17A ind/+ mice were significantly reduced after anti-GR-1 treatment ( Figure 6B ), suggesting that increased ROS serum levels in the K14IL-17A ind/+ mice are at least partially mediated by neutrophil granulocytes. Neutrophil granulocytes were also reduced in the spleen (data not shown) and exemplarily in 3 pooled aortas under application of anti-GR1 ( Figure 6D ). In parallel, a reduction of the vascular superoxide levels in the aortas of the K14IL-17A ind/+ mice compared with untreated K14IL-17A ind/+ mice was seen ( Figure 6C ).
Blockade of Cytokines Downstream of IL-17A Attenuates Both Skin Disease and Vascular Phenotype in K14IL-17A ind/+ Mice
Because anti-TNFα (etanercept) is frequently used to treat patients with severe psoriasis and TNF-α tended to be increased in the serum and the skin of K14IL-17A ind/+ mice ( Figure IIIA in the online-only Data Supplement), the K14IL-17A ind/+ mice were treated for a maximum of 10 weeks with anti-TNFα. As dermal and systemic levels of IL-6 were increased in K14IL-17A ind/+ mice and we had already been able to show an improvement of skin pathology with reduced skin thickness and less infiltrating CD11b + cells under anti-IL6 treatment ( Figure ID in the online-only Data Supplement), 22 we also used anti-IL-6 in another approach, which is approved for the treatment of refractory rheumatoid arthritis, 35 for further analysis. Both treatment regimen led to a significant improvement in skin pathology shown by reduced psoriasis area and severity index score ( Figure 7A mice was attenuated ( Figure 7E) , and under IL-6 also a slight improvement was noticed. These findings clearly strengthen the concept that both skin and vascular disease are closely linked by inflammatory mechanisms.
Discussion
We demonstrate here with an experimental approach a causative link between dermal IL-17A production in the skin and systemic vascular dysfunction. Our findings demonstrate the feasible role of IL-17A in linking skin and vascular disease, cytokine dissemination, and the knock-on effect of neutrophil granulocytes invading the vessel wall to induce vascular oxidative stress, inflammation, and dysfunction, leading to arterial hypertension and even premature death.
The K14IL-17A ind/+ mice have elevated IL-17A levels in the serum-most likely because of the permeability of the skin. This is comparable to psoriasis patients, where a positive correlation between the psoriasis area and severity index score and the serum IL-17 level has been described. 26, 27 Elevated IL-17A serum levels have also been reported for the imiquimod-induced psoriasis-like skin disease (≈20-40 pg/ mL in IMQ-treated wildtype mice, barely detectable in control mice), 36 although less in comparison to the K14IL-17A ind/+ mice, which can be explained by the smaller area of affected skin. The elevated IL-17A levels in the serum of the K14IL-17A ind/+ mice were accompanied by increased numbers of CD11b + cells-mostly neutrophil granulocytes-in the blood (Figure 2A-2C) . Independently of psoriasis, it has been shown that IL-17 induces hypertension by decreasing endothelial production of nitric oxide and that IL-17-mediated endothelial dysfunction can be normalized by an IL-17 neutralizing antibody. 37 Nuygen et al thus claimed that inhibitors of IL-17 may be useful as antihypertensive drugs in IL-17-associated autoimmune diseases. 37 Vascular dysfunction and hypertension in the K14-IL-17A ind/+ mice was associated with enhanced vascular O 2 − and ONOO − production, presumably driven by phagocytic NOX-2 (NADPH-oxidase 2) and a simultaneous upregulation of iNOS expression. We also found increased MPO levels in aortas of K14IL-17A ind/+ mice. MPO, mostly set free by degranulation of leukocytes, is known to have a profound adverse effect on vascular tone and resistance of vessels 38 because of its capacity to oxidize NO. In the K14IL-17A ind/+ mice, CD11b + GR1 + F4/80 − cells are elevated in the aorta. IL-17A is a crucial cytokine in neutrophil activation and recruitment. 9, 39 The invading neutrophil granulocytes might be a cellular source of both MPO and NADPH-oxidase in the animal model of K14IL-17A ind/+ mice, causing vascular inflammation and dysfunction. In line with this, a pilot patient study showed evidence for vascular inflammation in the aortas of patients with moderate-to-severe psoriasis compared with matched healthy controls. 40 It was shown recently that in angiotensin II-induced arterial hypertension, aortas were infiltrated with CD11b + Gr-1 low F4/80 + macrophages and CD11b + Gr-1 high F4/80 − neutrophils and that ablation of lysozyme-M + CD11b + myelomonocytic cells improved vascular dysfunction and reduced arterial hypertension. 31 Especially, neutrophil-derived IL-6 or cathelicidin CRAMP 41 can act as a switch between neutrophil and monocyte recruitment, 42 leading to an enhanced rise in proinflammatory macrophages in the inflamed tissue vessel wall. The fact that short-term neutrophil depletion by anti-GR-1 improved vascular oxidative stress, but not vascular function could be because of knock-on effects of neutrophils on other inflammatory cells, which could not be reversed by the brief duration of the treatment. We therefore suggest that hypertension in K14IL-17A ind/+ mice might result from the vascular dysfunction/inflammation, accompanied by myocardial hypertrophy and increased cardiac NADPH oxidase activity ( Figure 1C) .
Our experiments antagonizing cytokines downstream of IL-17A signaling point to a possible benefit of specific antiinflammatory treatment to attenuate not only skin disease, but also-at least partially-the related vascular disease. Small clinical trials made similar observations, showing that anti−TNF-α treatment improved vascular dysfunction in rheumatoid arthritis, 43 another IL-17A triggered autoimmune disease accompanied by CVD. But effects of biological treatment on the vascular system have to be considered cautiously. Although a cardioprotective effect has been noticed under anti-TNF-α treatment in psoriasis 44 and methotrexate in psoriasis or rheumatoid arthritis, 45 increased cardiovascular events under biological treatment of psoriasis with antibodies to the shared p40 subunit of IL-12 and interleukin-23 as potential downstream effectors of IL-17 have been described. 46 IL-17A has been characterized as a cytokine that triggers hypertension, 37 vascular dysfunction, 10 and also atherosclerosis. 47 Taleb et al demonstrated that in vivo administration of IL-17 reduces vascular T cell infiltration and limits atherosclerosis development. 48 However, IL-17A can also confer protection to the vasculature in the continuum of atherogenesis and its consequences, such as plaque rupture. Gistera et al 49 could show a decreased stability of atherosclerotic plaques when inhibiting IL-17 through neutralizing antibodies, suggesting that patients treated with IL-17 receptor blockers should be closely monitored for the appearance of cardiovascular events. 49 These findings show that the role of IL-17A in atherosclerosis is multifunctional and reflects the outbalanced immunologic response in this complex chronic inflammatory disease. Therefore, more studies will be needed to understand whether the GR-1 + immune cells or the cytokines downstream of IL-17A might be useful targets to treat the cardiovascular sequela of severe psoriasis.
Our patient survey confirmed the correlation between psoriasis and the prevalence of hypertension, myocardial infarction, and coronary artery disease (see Figure VI in the online-only Data Supplement). This was controversially discussed in the past as some trials showed the association 6,7 and some failed. 50, 51 We further strengthen the concept that hypertension (next to diabetes mellitus and smoking) is independently associated with psoriasis. This is in line with previous observations demonstrating that severe psoriasis is an independent risk factor for cardiovascular mortality besides other traditional cardiovascular risk factors 6 and that psoriatic patients have a heavier burden of the development CVD events. 52 In conclusion, our study indicates that (1) arterial hypertension and vascular disease is correlated with psoriasis-like skin disease in both mice and humans and that (2) the K14IL-17A ind/+ mice represent a viable model to further study the mechanistic link between psoriasis-like skin inflammation and vascular inflammation/dysfunction in the absence of other cardiovascular risk factors.
